← All trials
NCT07197944
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2025
- Primary completion
- Oct 23, 2028
- Completion date
- Feb 28, 2032
- First posted
- Sep 30, 2025
- Last posted
- Sep 30, 2025
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zealand PharmaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.